CDC. Data and statistics on congenital heart defects | CDC. Centers for Disease Control and Prevention. Published September 19, 2023. Accessed October 6, 2023. https://www.cdc.gov/ncbddd/heartdefects/data.html
Congenital disorders. Accessed October 6, 2023. https://www.who.int/news-room/fact-sheets/detail/birth-defects
Gilboa SM, Devine OJ, Kucik JE et al (2016) Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation 134(2):101–109. https://doi.org/10.1161/CIRCULATIONAHA.115.019307
Article PubMed PubMed Central Google Scholar
Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M (2014) Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 130(9):749–756. https://doi.org/10.1161/CIRCULATIONAHA.113.008396
Mandalenakis Z, Giang KW, Eriksson P et al (2020) Survival in children with congenital heart disease: have we reached a peak at 97%? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 9(22):e017704. https://doi.org/10.1161/JAHA.120.017704
Wu M, Lu C, Chen H, Kao F, Huang S (2018) Adult congenital heart disease in a nationwide population 2000–2014: epidemiological trends, arrhythmia, and standardized mortality ratio. J Am Heart Assoc 7(4):e007907. https://doi.org/10.1161/JAHA.117.007907
Article PubMed PubMed Central Google Scholar
Tutarel O, Kempny A, Alonso-Gonzalez R et al (2014) Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J 35(11):725–732. https://doi.org/10.1093/eurheartj/eht257
Dellborg M, Giang KW, Eriksson P et al (2023) Adults with congenital heart disease: trends in event-free survival past middle age. Circulation 147(12):930–938. https://doi.org/10.1161/CIRCULATIONAHA.122.060834
Article CAS PubMed Google Scholar
Gurvitz M, Dunn JE, Bhatt A et al (2020) Characteristics of adults with congenital heart defects in the United States. J Am Coll Cardiol 76(2):175–182. https://doi.org/10.1016/j.jacc.2020.05.025
Article PubMed PubMed Central Google Scholar
Bergh N, Skoglund K, Fedchenko M et al (2023) Risk of heart failure in congenital heart disease: a nationwide register-based cohort study. Circulation 147(12):982–984. https://doi.org/10.1161/CIRCULATIONAHA.122.061546
Mandalenakis Z, Rosengren A, Lappas G et al (2018) Atrial fibrillation burden in young patients with congenital heart disease. Circulation 137(9):928–937. https://doi.org/10.1161/CIRCULATIONAHA.117.029590
Fedchenko M, Mandalenakis Z, Giang KW, Rosengren A, Eriksson P, Dellborg M (2020) Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease—a nationwide study. Eur Heart J 42(26):2577–2586. https://doi.org/10.1093/eurheartj/ehaa874
Article PubMed Central Google Scholar
Burstein DS, Rossano JW, Griffis H et al (2021) Greater admissions, mortality and cost of heart failure in adults with congenital heart disease. Heart 107(10):807–813. https://doi.org/10.1136/heartjnl-2020-318246
Article CAS PubMed Google Scholar
Zomer AC, Vaartjes I, van der Velde ET et al (2013) Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol 168(3):2487–2493. https://doi.org/10.1016/j.ijcard.2013.03.003
Article CAS PubMed Google Scholar
Engelings CC, Helm PC, Abdul-Khaliq H et al (2016) Cause of death in adults with congenital heart disease - an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol 211:31–36. https://doi.org/10.1016/j.ijcard.2016.02.133
Verheugt CL, Uiterwaal CSPM, van der Velde ET et al (2010) Mortality in adult congenital heart disease. Eur Heart J 31(10):1220–1229. https://doi.org/10.1093/eurheartj/ehq032
Zengin E, Sinning C, Blaum C et al (2021) Heart failure in adults with congenital heart disease: a narrative review. Cardiovasc Diagn Ther 11(2):529–537. https://doi.org/10.21037/cdt-20-632
Article PubMed PubMed Central Google Scholar
Diller GP, Kempny A, Alonso-Gonzalez R et al (2015) Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 132(22):2118–2125. https://doi.org/10.1161/CIRCULATIONAHA.115.017202
Sabanayagam A, Cavus O, Williams J, Bradley E (2018) Management of heart failure in adult congenital heart disease. Heart Fail Clin 14(4):569–577. https://doi.org/10.1016/j.hfc.2018.06.005
Article PubMed PubMed Central Google Scholar
Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L (1997) Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96(5):1507–1512. https://doi.org/10.1161/01.cir.96.5.1507
Article CAS PubMed Google Scholar
Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, Therrien J, Benson L, Siu S, Webb G (2001) Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 87(5):660–3, A11. https://doi.org/10.1016/s0002-9149(00)01452-1
Article CAS PubMed Google Scholar
Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, Schiller NB, Foster E (2001) Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol 88(11):1314–1316. https://doi.org/10.1016/s0002-9149(01)02098-7
Article CAS PubMed Google Scholar
Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A (2019) Medical therapy for systemic right ventricles: a systematic review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(12):1564–1578. https://doi.org/10.1016/j.jacc.2018.08.1030
Doughan ARK, McConnell ME, Book WM (2007) Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol 99:704–706
Article CAS PubMed Google Scholar
Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C (2010) Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young 20(6):615–619. https://doi.org/10.1017/S1047951110000764
Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM (2006) A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol 22(9):769–772. https://doi.org/10.1016/s0828-282x(06)70293-8
Article PubMed PubMed Central Google Scholar
Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R (2007) A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol 114(2):241–246. https://doi.org/10.1016/j.ijcard.2006.01.048
Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O (2020) Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol 300:137–140. https://doi.org/10.1016/j.ijcard.2019.06.031
Yan L, Loh JK, Le Tan J (2021) Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – Experience from a tertiary centre in Singapore. International Journal of Cardiology Congenital Heart Disease 6:100268. https://doi.org/10.1016/j.ijcchd.2021.100268
Zandstra TE, Nederend M, Jongbloed MRM et al (2021) Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart 107(21):1725–1730. https://doi.org/10.1136/heartjnl-2020-318074
Article CAS PubMed Google Scholar
Fusco F, Scognamiglio G, Merola A et al (2023) Safety and efficacy of sacubitril/valsartan in patients with a failing systemic right ve
Comments (0)